Related Experiment Video
Updated: Mar 19, 2026

Stimulation of Notch Signaling in Mouse Osteoclast Precursors
Published on: February 28, 2017
Turning over renal osteodystrophy dogma: direct actions of FGF23 on osteoblast β-catenin pathway
Susan C Schiavi1, Rosa M A Moysés2
1PreciThera, Montreal, Quebec, Canada.
Abstract:
Although recognized as a major complication of chronic kidney disease (CKD), the pathophysiology of the CKD-related mineral and bone disorder (CKD-MBD) is not completely understood. Recently, the inhibition of Wnt/β-catenin pathway in osteocytes by sclerostin has been shown to play a role in CKD-MBD. The study by Carrilo-Lopez et al. confirms this inhibition in an experimental model of CKD. Moreover, they describe direct actions of FGF23-Klotho on osteoblasts, increasing the expression of DKK1, another Wnt/β-catenin pathway inhibitor.
Insights
Chronic kidney disease (CKD) mineral and bone disorder (CKD-MBD) involves Wnt/β-catenin pathway inhibition. FGF23-Klotho directly increases DKK1 expression in osteoblasts, contributing to CKD-MBD.
Area of Science:
- Nephrology
- Endocrinology
- Bone Biology
Background:
- Chronic kidney disease (CKD) is linked to mineral and bone disorder (CKD-MBD).
- Sclerostin's inhibition of the Wnt/β-catenin pathway in osteocytes is implicated in CKD-MBD.
- The precise mechanisms underlying CKD-MBD pathophysiology require further elucidation.
Purpose of the Study:
- To investigate the role of Wnt/β-catenin pathway inhibition in CKD-MBD.
- To explore the direct effects of FGF23-Klotho on osteoblasts and their contribution to CKD-MBD.
Main Methods:
- Utilized an experimental model of chronic kidney disease (CKD).
- Assessed the expression of Wnt/β-catenin pathway inhibitors, including DKK1.
- Examined the direct actions of FGF23-Klotho on osteoblast function.
Main Results:
- Confirmed sclerostin-mediated inhibition of the Wnt/β-catenin pathway in osteocytes within a CKD model.
- Demonstrated direct effects of FGF23-Klotho on osteoblasts.
- Showed that FGF23-Klotho increases the expression of DKK1, a Wnt/β-catenin pathway inhibitor, in osteoblasts.
Conclusions:
- Sclerostin plays a role in CKD-MBD pathophysiology through Wnt/β-catenin pathway inhibition.
- FGF23-Klotho directly influences osteoblasts, upregulating DKK1 expression.
- These findings provide new insights into the complex mechanisms of CKD-MBD.
Related Concept Videos
TGF - β Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
Hedgehog Signaling Pathway
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...

